BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Advances in acute myeloid leukemia (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax. The association between BCL2 expression and patient outcome was analyzed in a series of 176 consecutive AML patients at diagnosis (Dx), post-induction (PI), complete remi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diagnostics (Basel)
Main Authors: Bilbao-Sieyro, Cristina, Rodríguez-Medina, Carlos, Florido, Yanira, Stuckey, Ruth, Sáez, María Nieves, Sánchez-Sosa, Santiago, González Martín, Jesús María, Santana, Guillermo, González-Pérez, Elena, Cruz-Cruz, Naylén, Fernández, Rosa, Molero Labarta, Teresa, Gomez-Casares, María Teresa
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7762084/
https://ncbi.nlm.nih.gov/pubmed/33291851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics10121048
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados